Buscar
Verona Pharma PLC
VRNAAñadir a la lista de seguimiento
106.910USD
0.0000.00%
Cierre 06/18, 16:00（ET）Cotizaciones retrasadas 15 min
73.55BCap. mercado
PérdidaP/E TTM
Más Datos de Verona Pharma PLC Compañía
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Información de Verona Pharma PLC
Símbolo de cotizaciónVRNA
Nombre de la empresaVerona Pharma PLC
Fecha de salida a bolsaMar 30, 2005
Director ejecutivoDr. David S. Zaccardelli, Pharm.D.
Número de empleados209
Tipo de seguridadDepository Receipt
Fin del año fiscalMar 30
DirecciónRiverside
CiudadLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Teléfono442032834200
Sitio Webhttps://www.veronapharma.com/
Símbolo de cotizaciónVRNA
Fecha de salida a bolsaMar 30, 2005
Director ejecutivoDr. David S. Zaccardelli, Pharm.D.
Ejecutivos de Verona Pharma PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Verona Pharma PLC?
Los cinco principales accionistas de Verona Pharma PLC son: Mr. Andrew Fisher
¿Cuántas instituciones poseen acciones de Verona Pharma PLC (VRNA)?
A fecha de 2025Q3, 467 instituciones poseen acciones de Verona Pharma PLC, con un valor de mercado combinado de aproximadamente 76.61M, lo que representa el 88.88% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -7116945.00.
